Page 2 - Alex Speiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted on 335 Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced that it has appointed David E. Nichols, Ph.D., a renowned expert on the pharmacology and medicinal chemistry of psychedelics, as its Director of Molecular Pharmacology. He will collaborate closely with his son, Charles Nichols, Ph.D., the scientific founder of Eleusis, in an effort to accelerate the transformation of psychedelics into medicines. Dr. David Nichols is an Adjunct Profe...

(1) Acquisition of Kalypso accelerates the clinical development of psychedelic infusion therapies ELE-Ket+ and ELE-Psilo+ are psychedelic infusion therapies in clinical development for adjunctive treatment of major depressive disorder; initiation of Phase 2 clinical trials expected in Q4 2021 Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the launch of its clinical development of psychedelic infusion therapies and acquisition of Kalypso Wellness Centers ("Kalypso"), a leading provider of ketamine i...